Page 7 - Oncimmune Immuno News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Oncimmune Holdings Collaboration demonstrates the utility of autoantibodies in Methotrexate and Tocilizumab treatment selection
7:15 am
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the publication by PLOS ONE of a study, supported by the Oncimmune’s ImmunoINSIGHTS team, which analysed autoantibodies in patients with newly diagnosed Rheumatoid Arthritis (RA) who were treated with either Tocilizumab or Methotrexate monotherapy. This work significantly expanded the biomarkers commonly measured in RA patients to develop a detailed picture of the immune response to the disease and its treatment.
The aim of the study was to develop a set or panel of predictive biomarkers to identify an early response in RA patients to Methotrexate or Tocilizumab, Roche’s interleukin-6 (IL-6) receptor inhibitor. ....

Adamm Hill , Oncimmune Immuno , Oncimmune Holdings , Rheumatoid Arthritis , Rheumatoid Factor , முடக்கு கீல்வாதம் , முடக்கு காரணி ,